BCAB Stock Analysis: Buy, Sell, or Hold?
BCAB - BioAtla, Inc. Common Stock
$0.27
-0.02 (-6.60%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 19, 2026
Get Alerted When BCAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called BCAB this week
29% bullish • 10 bearish
29% bullish • 10 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BCAB is down 23.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BCAB is down 23.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAB is currently trading at $0.27, which is considered oversold relative to its 30-day fair value range of $0.27 to $0.63.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $0.25, while resistance sits at $0.39. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+3372.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $0.25, while resistance sits at $0.39. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.00 (+3372.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.27 -
$0.63
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding BCAB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 3372.2% below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to -23.8% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.27 -
$0.63
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.25
Resistance Level
$0.39
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.31
Wall Street Target
$10.00
(+3372.2%)
Revenue Growth (YoY)
31.6%
Last updated: January 31, 2026 3:06 AM ET
Data refreshes hourly during market hours. Next update: 4:06 AM
Data refreshes hourly during market hours. Next update: 4:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
Advanced BCAB Option Strategies
Professional options setups generated by AI based on today's BCAB price and gamma walls.
